Vivos Therapeutics, Inc. Long-Term Debt, Maturity, Year Five
Vivos Therapeutics, Inc. (VVOS) had Long-Term Debt, Maturity, Year Five of $31.00 thousand as of 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Four and Five
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive · last filed 2026-04-15
- 2025-12-31: Long-Term Debt, Maturity, Year Five $31.00K.
| Period end | Long-Term Debt, Maturity, Year Five |
|---|---|
| 2025-12-31 | $31.00K 10-K · filed 2026-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |